Pozen MT-100 committee review postponed
Executive Summary
May review of Pozen's MT-100 migraine treatment by FDA's Peripheral & Central Nervous System Drugs Advisory Committee is postponed due to "FDA scheduling conflicts." The meeting was to address potential risk of tardive dyskinesia with MT-100, a combination of metoclopromide and naproxen (1"The Pink Sheet" Jan. 3, 2005, In Brief). The company is discussing future meeting dates with FDA; the only tentative date scheduled for the committee is Aug. 4...